# Kira Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kira-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.kirapharma.com
- Total disclosed funding: $100M
- Latest round: Series B (Jan 7, 2021)
- Investors on record: 9

## About

Kira Pharmaceuticals Ltd. is a US-based biotech company dedicated to developing innovative therapies targeting the complement system for autoimmune and inflammatory diseases.Founded in 2017, Kira Pharmaceuticals Ltd., headquartered in Cambridge, US, focuses on creating therapies that modulate immune responses in various diseases. The company was co-founded by Gonghua Pan and Wenru Song. Kira has successfully raised funding through four deals, with the most recent being a Series B round of USD 53.5 mn on January 7, 2021, co-led by RA Capital Management and Vivo Capital, with participation from APlus Partners and Foresite Capital, along with returning investors Qiming Venture Partners and Quan Capital.Kira Pharmaceuticals develops innovative therapies specifically targeting the complement system, crucial for various autoimmune and inflammatory diseases. Their primary offerings include investigational agents for conditions like IgA nephropathy, complement 3 glomerulopathy, and paroxysmal nocturnal hemoglobinuria. Utilizing the proprietary LOGIC platform, the company aims to enhance drug development processes and efficacy, targeting healthcare providers globally, including markets in the United States, China, and Australia.Kira Pharmaceuticals operates on a model emphasizing partnerships and collaborations with research institutions and healthcare organizations. Revenue is anticipated from successful clinical trials leading to the commercialization of their investigational products, particularly their lead asset, KP104. While specific pricing plans are undisclosed, strategic partnerships may include funding arrangements or shared revenue models contingent upon successful product development and approval.Kira Pharmaceuticals plans to utilize the recent Series B funding of USD 53.5 mn to advance their drug discovery platform and further develop complement therapies. The company is strategically targeting global markets for expansion, focusing on regions like the United States, China, and Australia. While specific timelines for new product launches and market entry are not detailed, the funding will support their initiatives to streamline development and bring innovative therapies to market.

## Funding rounds

- Series B, Jan 7, 2021, $54M — Vivo Capital, Qiming Venture Partners, Foresite Capital, RA Capital Management, Quan Capital, APlus Partners
- Series B, Nov 16, 2020, $28M — Qiming Venture Partners, Shanghai Jianyi Private Equity Fund Management, 6 Dimensions Capital, Quan Venture Capital
- Series A, Aug 1, 2018, $13M — Qiming Venture Partners, Shanghai Jianyi Private Equity Fund Management, 6 Dimensions Capital, Quan Capital
- Series A, Jul 1, 2017, $5M — Qiming Venture Partners, Shanghai Jianyi Private Equity Fund Management, 6 Dimensions Capital, Quan Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A, Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A, Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A, Series B
- Quan Venture Capital — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- APlus Partners — Series B